[
  {
    "ts": null,
    "headline": "Biotechnology Instruments Market Projected to Reach US$ 141.70 Billion by 2035 | Astute Analytica",
    "summary": "The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and high-margin consumables, the sector promises sustained scalability. Massive infrastructure investments, like Eli Lilly’s USD 4.5 billion campus, confirm a lucrative, long-term trajectory.Chicago, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global biotechnology instruments market size stood at USD 92.12 billion in 2025 and is expected to reach USD 141.70 billion by 2035 with a 4.",
    "url": "https://finnhub.io/api/news?id=2c6df170734f8e8f3423edb1075eb7203f0452c82d201cda5c037991f25d1254",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767803400,
      "headline": "Biotechnology Instruments Market Projected to Reach US$ 141.70 Billion by 2035 | Astute Analytica",
      "id": 138033035,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and high-margin consumables, the sector promises sustained scalability. Massive infrastructure investments, like Eli Lilly’s USD 4.5 billion campus, confirm a lucrative, long-term trajectory.Chicago, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global biotechnology instruments market size stood at USD 92.12 billion in 2025 and is expected to reach USD 141.70 billion by 2035 with a 4.",
      "url": "https://finnhub.io/api/news?id=2c6df170734f8e8f3423edb1075eb7203f0452c82d201cda5c037991f25d1254"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific (TMO) Valuation Check As New Obesity Registry And Key Updates Draw Investor Focus",
    "summary": "Thermo Fisher Scientific (TMO) is back in focus after enrolling the first patient in its PPD CorEvitas Obesity Registry, a real world data effort that intersects directly with obesity therapies and long term health outcomes. See our latest analysis for Thermo Fisher Scientific. The new obesity registry has arrived at a time when Thermo Fisher Scientific’s share price has been firming, with a 90 day share price return of 15.76% and a 1 year total shareholder return of 14.16%. This suggests...",
    "url": "https://finnhub.io/api/news?id=f5c367eedbe00c2840f3a51e18e18fef0a677d9e037d744a3be0c8c968277b2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767784184,
      "headline": "Thermo Fisher Scientific (TMO) Valuation Check As New Obesity Registry And Key Updates Draw Investor Focus",
      "id": 138025862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific (TMO) is back in focus after enrolling the first patient in its PPD CorEvitas Obesity Registry, a real world data effort that intersects directly with obesity therapies and long term health outcomes. See our latest analysis for Thermo Fisher Scientific. The new obesity registry has arrived at a time when Thermo Fisher Scientific’s share price has been firming, with a 90 day share price return of 15.76% and a 1 year total shareholder return of 14.16%. This suggests...",
      "url": "https://finnhub.io/api/news?id=f5c367eedbe00c2840f3a51e18e18fef0a677d9e037d744a3be0c8c968277b2f"
    }
  }
]